Aptevo Therapeutics PE Ratio 2014-2022 | APVO

Current and historical p/e ratio for Aptevo Therapeutics (APVO) from 2014 to 2022. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Aptevo Therapeutics PE ratio as of September 23, 2022 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Aptevo Therapeutics PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2022-09-23 3.12 1.20
2022-06-30 3.58 $2.60 1.38
2022-03-31 5.87 $-4.73 0.00
2021-12-31 7.87 $-4.82 0.00
2021-09-30 15.44 $-4.82 0.00
2021-06-30 22.43 $-5.49 0.00
2021-03-31 30.52 $-5.84 0.00
2020-12-31 36.65 $-3.31 0.00
2020-09-30 7.60 $-3.31 0.00
2020-06-30 8.35 $-5.41 0.00
2020-03-31 3.70 $-9.47 0.00
2019-12-31 9.16 $-10.36 0.00
2019-06-30 12.41 $-18.21 0.00
2019-03-31 12.60 $-22.13 0.00
2018-12-31 17.78 $-24.79 0.00
2018-09-30 71.12 $-24.79 0.00
2018-06-30 69.86 $7.56 9.24
2018-03-31 45.78 $8.26 5.54
2017-12-31 59.36 $10.36 5.73
2017-09-30 32.06 $0.00 0.00
2017-06-30 28.98 $-74.23 0.00
2017-03-31 28.84 $-69.05 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.016B $0.012B
Aptevo Therapeutics Inc. is a biotechnology company which focused on developing oncology and hematology therapeutics. The company's platform consists of ADAPTIR(TM). Its product pipeline includes WinRho (R) SDF, HepaGam B (R), VARIZIG(R) and IXINITY (R) which are in pre-clinical stage. Aptevo Therapeutics Inc. is based in Seattle, Washington.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $150.984B 9.16
GSK (GSK) United Kingdom $59.709B 7.17
Bio-Rad Laboratories (BIO.B) United States $12.433B 27.47
Biohaven Pharmaceutical Holding (BHVN) United States $10.873B 0.00
QIAGEN (QGEN) Netherlands $9.383B 15.71
Ginkgo Bioworks Holdings (DNA) United States $4.998B 0.00
Arcus Biosciences (RCUS) United States $1.819B 35.51
Myovant Sciences (MYOV) United Kingdom $1.614B 0.00
Emergent Biosolutions (EBS) United States $1.040B 6.03
ADC Therapeutics SA (ADCT) Switzerland $0.376B 0.00
Zymeworks (ZYME) Canada $0.305B 0.00
Enzo Biochem (ENZ) United States $0.105B 0.00
Gelesis Holdings (GLS) United States $0.081B 0.00
SQZ Biotechnologies (SQZ) United States $0.068B 0.00
Ambrx Biopharma (AMAM) United States $0.041B 0.00